Vanguard Capital Management
ALDX icon

Vanguard Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Vanguard Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.94M Buy
2,392,805
+31,009
+1% +$49.5K ﹤0.01% 3243
2026
Q2 		$5.03M Sell
2,361,796
-1,946
-0.1% -$3.34K ﹤0.01% 3119
2026
Q1 		$3.99M Buy
+2,363,742
New +$10.4M ﹤0.01% 3142

Other funds holding ALDX

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Vanguard Capital Management's ALDX Position: Q3 2026 in Review

Vanguard Capital Management increased its Aldeyra Therapeutics (ALDX) stake by 1.3% in Q3 2026, buying an estimated $49.5K and bringing the position to 2,392,805 shares worth $2.94M. The position accounts for ﹤0.01% of the portfolio, ranked #3243.

Vanguard Capital Management first reported a position in ALDX in Q1 2026 and has held it in 3 quarters since. The position peaked at $5.03M in Q2 2026. 63 funds tracked by Wall St. Rank hold ALDX as of Q3 2026.

  • Vanguard Capital Management held 2,392,805 shares of Aldeyra Therapeutics worth $2.94M as of Q3 2026.
  • Vanguard Capital Management bought 31,009 Aldeyra Therapeutics shares in Q3 2026, an estimated $49.5K.
  • Aldeyra Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3243 holding.
  • Vanguard Capital Management first reported a position in Aldeyra Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Aldeyra Therapeutics position peaked at $5.03M in Q2 2026.
  • 63 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.